Core Viewpoint - The blood dialysis machine market in China is experiencing rapid growth, with the market size expected to reach 4.131 billion yuan by 2025, reflecting a year-on-year increase of 6.4% [1][6]. Industry Overview - Blood dialysis machines, also known as artificial kidneys, are essential medical devices for treating renal failure and uremia, consisting of a blood monitoring alarm system and a dialysis liquid supply system [3][4]. - The increasing elderly population and rising prevalence of chronic kidney diseases are driving the demand for blood dialysis machines [5][6]. Market Size and Growth - The market size for blood dialysis machines in China is projected to grow significantly, driven by an aging population and an increasing number of patients requiring dialysis treatment [1][6]. - The number of patients undergoing dialysis in China is expected to rise from 385,100 in 2015 to 1,027,300 by 2024, with male patients making up a significant portion of this demographic [5][6]. Competitive Landscape - The Chinese blood dialysis machine industry is primarily dominated by foreign companies such as Fresenius Medical, B. Braun, Baxter, and Nipro, indicating substantial room for domestic companies to capture market share [7][8]. - Domestic companies are enhancing their R&D capabilities, leading to improvements in technology and product quality, which positions them to compete more effectively against international brands [7][8]. Industry Development Trends - The process of domestic substitution for blood dialysis machines is accelerating, with local companies focusing on core technology and key component development to reduce reliance on foreign brands [10][11]. - Future technological advancements in blood dialysis machines will focus on smart and precise upgrades, integrating IoT and AI for improved monitoring and safety [11][12]. - The application scenarios for blood dialysis machines are expanding beyond traditional hospitals to include community healthcare settings and home dialysis solutions, driven by the increasing demand for accessible and convenient treatment options [12].

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向天益医疗提问："请问最近一期公司的股东人数是多少？" 针对上述提问，天益医疗回应称："尊敬的投资者，您好，截至2026年2月13日，公司股东总数为4,958 户，感谢您的关注。" ...

Group 1 - Ningbo Tianyi Medical Equipment Co., Ltd. has invested 50 million RMB to establish Ningbo Tianyi Medical Technology Co., Ltd., holding 100% of the shares [1] - Ningbo Tianyi Medical Technology Co., Ltd. was founded on December 19, 2024, with a registered capital of 50 million RMB and is located in Ningbo City [1] - The company is involved in various sectors including the production and sale of medical devices, pharmaceuticals, and health consulting services [1] Group 2 - The company is authorized to engage in the production of first, second, and third-class medical devices, as well as the production and wholesale of pharmaceuticals [1] - Additional activities include technical services, technology development, and the sale of rubber and plastic products [1] - The company is also permitted to conduct import and export activities related to goods and technology [1]

Core Viewpoint - Tianyi Medical (301097) experienced a slight decline in stock price, closing at 56.22 yuan on February 3, 2026, with a trading volume of 14,600 hands and a total transaction amount of 81.14 million yuan [1]. Group 1: Stock Performance - On February 3, 2026, the stock saw a net inflow of main funds amounting to 67.67 thousand yuan, representing 0.83% of the total transaction amount [1]. - Retail investors contributed a net inflow of 485.18 thousand yuan, accounting for 5.98% of the total transaction amount, while speculative funds experienced a net outflow of 552.86 thousand yuan, which is 6.81% of the total transaction amount [1]. Group 2: Financing and Margin Information - On the same day, the financing buy amounted to 920.57 thousand yuan, while financing repayment was 971.33 thousand yuan, resulting in a net repayment of 50.75 thousand yuan [2]. - The margin trading balance stood at 55.43 million yuan, with no shares sold or repaid in the securities lending segment [2]. Group 3: Financial Performance - For the first three quarters of 2025, Tianyi Medical reported a main revenue of 387 million yuan, reflecting a year-on-year increase of 24.14% [3]. - The net profit attributable to shareholders reached 20.09 million yuan, up 216.81% year-on-year, while the net profit excluding non-recurring items was 8.41 million yuan, showing a significant increase of 762.11% [3]. - In Q3 2025 alone, the company achieved a main revenue of 160 million yuan, a 48.03% increase year-on-year, and a net profit of 10.61 million yuan, which is a 227.86% increase year-on-year [3]. - The company's debt ratio is reported at 42.92%, with an investment loss of 7.25 million yuan and financial expenses of 767.7 thousand yuan, while the gross profit margin is at 38.39% [3]. Group 4: Analyst Ratings - In the last 90 days, one institution has issued a buy rating for Tianyi Medical [4].

Group 1 - The core viewpoint of the article is that Tianyi Medical (301097) is actively engaging with investors and providing updates on its shareholder status and contractual agreements [1] - As of January 30, 2026, the total number of shareholders for the company is reported to be 5,165 [1] - The distribution contract signed with Fresenius subsidiary ProCure Medical GmbH is currently being executed as planned, with the first year of formal contract effectiveness set for 2026 [1] - The company will arrange for the gradual delivery of products as per the contract terms starting in 2026 [1]

Group 1 - The company has signed a five-year procurement contract with PMG, effective from January 1, 2024, with an expected procurement amount of 40 million USD by 2026 [2] - As of January 30, 2026, the total number of shareholders for the company is 5,165 [2] - The distribution contract signed with a subsidiary of Fresenius in October 2024 is currently being executed normally, with product deliveries scheduled to commence as per the contract in 2026 [2]

Core Viewpoint - Tianyi Medical (301097) has announced a significant decline in its expected net profit for the fiscal year 2025, projecting a loss between 18 million to 11 million yuan, marking a drastic decrease of 1,378.49% to 2,319.35% compared to the previous year [1] Financial Performance - As of February 2, 2026, Tianyi Medical's stock closed at 57.11 yuan, down 4.71% from the previous trading day, with a total market capitalization of 3.366 billion yuan [1] - The stock opened at 57.8 yuan, reached a high of 59.2 yuan, and a low of 55.13 yuan, with a trading volume of 1.44 billion yuan and a turnover rate of 8.74% [1] Earnings Forecast - The company expects a net profit attributable to shareholders to be between -18 million to -11 million yuan for 2025, indicating a substantial decline from the previous year's performance [1] - The forecasted net profit after excluding non-recurring gains and losses is anticipated to be between -13 million to -8 million yuan [1] - The decline in performance is attributed to several factors, including the provision for administrative penalties, investment losses from the integration of the CRRT business, increased foreign exchange losses due to fluctuations in the US dollar, and increased provisions for inventory impairment [1]

Core Viewpoint - Tianyi Medical announced an expected net profit loss of 18 million to 11 million yuan for the fiscal year 2025, primarily due to operational pressures following the completion of the CRRT business acquisition from NKS [1] Group 1: Financial Performance - The company anticipates a net profit loss ranging from 18 million to 11 million yuan for 2025 [1] - The expected loss is attributed to various factors including business adjustments, supply chain issues, personnel changes, organizational restructuring, and information system modifications [1] Group 2: Business Operations - Tianyi Medical's joint venture, Ningbo Tianhui Yi Enterprise Management Co., Ltd., and its wholly-owned subsidiary TYHC International PTE. LTD. have completed the acquisition of the CRRT business from NKS [1] - 2025 will be the first year of operations post-acquisition, which is expected to impact the company's financial performance significantly [1]

Financial Performance - The company expects a net profit of approximately -18 million CNY for the year 2025, representing a decline of 2,319.35% compared to the same period last year[5]. - The projected operating revenue for 2025 is between 480 million CNY and 640 million CNY, compared to 418.96 million CNY in the previous year[5]. - The financial data presented is preliminary and will be detailed in the annual report for 2025[9]. Operational Changes - The company has completed the delivery of the CRRT business held by NKS, which is expected to impact operational performance due to integration and organizational adjustments[8]. - The company plans to account for potential administrative penalties as indicated in the notice received from the Ningbo Market Supervision Administration[8]. Risk Factors - The company has experienced increased foreign exchange losses due to fluctuations in the USD exchange rate[8]. - Inventory levels have expanded year-on-year, leading to an increase in inventory impairment provisions compared to the previous year[8]. - Investors are advised to make cautious decisions and be aware of investment risks[10]. Communication and Compliance - The company has communicated with the accounting firm regarding the preliminary financial estimates, with no significant discrepancies reported[6]. - The company will provide further updates and disclosures as required by regulatory authorities[9].

Core Viewpoint - Tianyi Medical's subsidiary, Ningbo Tianyi Pharmaceutical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for blood dialysis concentrates, aimed at treating patients with acute and chronic renal failure [1] Product Registration - The registered product is intended for use in blood dialysis treatment for patients suffering from acute and chronic renal failure [1] - The actual sales performance of the registered product will depend on future market promotion efforts [1] Financial Impact - The company is currently unable to predict the impact of this product on future operating revenue [1]